ReviewDigestive diseases and sciences2017
Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
Review in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Efficacy and safety of triple therapy with vonoprazan forWorld journal of gastroenterology · 2025Trial
- TargetingFrontiers in cellular and infection microbiology · 2025Article
- Overcoming the effects of increasing antimicrobial resistance onExpert review of gastroenterology & hepatology · 2024Review
- Review
- Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice.Journal of clinical laboratory analysis · 2023Review
- Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies forTropical medicine and infectious disease · 2023Review
- Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study.Journal of gastroenterology · 2023Article
- Effectiveness of vonoprazan-based regimens compared with proton pump inhibitor-based regimens as first-lineFrontiers in pharmacology · 2023Article
- Rescue therapy for refractoryTherapeutic advances in gastroenterology · 2023Review
- Multidrug resistance inFrontiers in microbiology · 2023Review
- Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms ofGut and liver · 2021Review
- Revisiting Therapeutic Strategies forMolecules (Basel, Switzerland) · 2021Review
- Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-LineYonsei medical journal · 2021Article
- Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.Digestive diseases and sciences · 2020Review
- Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans.Acta pharmacologica Sinica · 2020Article
- Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment ofTherapeutic advances in gastroenterology · 2020Article
- A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report.Journal of gastroenterology · 2019Article
- Current status of first- and second-lineTherapeutic advances in gastroenterology · 2019Article
- Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?World journal of gastrointestinal pharmacology and therapeutics · 2018Review
- Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication ofBiomedical reports · 2018Article
Corrections and comments
- Commented on by
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEradication therapies for Helicobacter pylori infection are advancing as new acid inhibitory reagents approved. The aim of this study was to assess the efficacy and safety of vonoprazan-based triple treatment. MATERIALS AND
methodsTriple therapy with vonoprazan and two antibiotics (amoxicillin and clarithromycin or metronidazole) received focus in this analysis. We performed a multicenter retrospective study of patients who received vonoprazan-based eradication therapy between February 2015 and February 2016 and conducted a review of the literature.
resultsThe eradication rate among the 799 patients in our multicenter study was 94.4% (95% confidence interval [CI] 92.6-96.2%) in the per-protocol analysis for first-line treatment (with vonoprazan 20 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg, twice a day for 7 days) and 97.1% (95% CI 93.0-101.1%) for second-line treatment (with vonoprazan 20 mg, amoxicillin 750 mg, and metronidazole 250 mg, twice a day for 7 days). The overall incidence of adverse events was 4.4% in an intention-to-treat analysis with no patients hospitalized. In a literature review, six reports, in which 1380 patients received vonoprazan-based first-line eradication therapy, were included and were all reported by Japanese researchers. The eradication success rates in per-protocol analysis were between 85 and 93%, which was roughly the same among the studies.
conclusionsVonoprazan-based triple therapy was effective and safe for Helicobacter pylori eradication in real-world experience, confirmed by a multicenter study and a review of the pertinent literature.
Indexed as
Identifiers
28664410What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.